Trial · NCT03015129

A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer

NCT03015129, Phase 2, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2024-02-06

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer. Trials, record NCT03015129. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03015129

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
NCT number: NCT03015129
Status: Completed
Phases: Phase 2
Enrollment: 80 participants, actual
Lead sponsor: Memorial Sloan Kettering Cancer Center
Conditions: Endometrial Cancer, Endometrial Carcinosarcoma, Endometrial Carcinoma, Endometrial Cancer Recurrent, Endometrial Carcinoma, Recurrent
Interventions: Durvalumab, Tremelimumab
First posted: 2017-01-09
Last updated: 2024-02-06
Results first posted: 2024-02-06

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Treatment Efficacy Determined by Measuring the Overall Response Rate	Up to 72 months	Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Treatment Efficacy Determined by Measuring the Overall Response Rate	Up to 72 months		Participants	NUMBER

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Treatment Efficacy Determined by Measuring the Overall Response Rate	Durvalubmab		5		Participants
Treatment Efficacy Determined by Measuring the Overall Response Rate	Durvalubmab + Tremelimumab		4		Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Durvalubmab	40
Overall Study	STARTED	Durvalubmab + Tremelimumab	40
Overall Study	COMPLETED	Durvalubmab	0
Overall Study	COMPLETED	Durvalubmab + Tremelimumab	0
Overall Study	NOT COMPLETED	Durvalubmab	40
Overall Study	NOT COMPLETED	Durvalubmab + Tremelimumab	40

Source ClinicalTrials.gov

Adverse events254

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Abdominal distension	Gastrointestinal disorders	Durvalubmab	0	40
other	Abdominal distension	Gastrointestinal disorders	Durvalubmab + Tremelimumab	2	40
other	Abdominal pain	Gastrointestinal disorders	Durvalubmab	25	40
other	Abdominal pain	Gastrointestinal disorders	Durvalubmab + Tremelimumab	12	40
other	Adrenal insufficiency	Endocrine disorders	Durvalubmab	2	40
other	Adrenal insufficiency	Endocrine disorders	Durvalubmab + Tremelimumab	0	40
other	Allergic rhinitis	Respiratory, thoracic and mediastinal disorders	Durvalubmab	0	40
other	Allergic rhinitis	Respiratory, thoracic and mediastinal disorders	Durvalubmab + Tremelimumab	2	40
other	Anal pain	Gastrointestinal disorders	Durvalubmab	3	40
other	Anal pain	Gastrointestinal disorders	Durvalubmab + Tremelimumab	0	40

1 to 10 of 254Source ClinicalTrials.gov

See all 254 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Durvalubmab	2	40
Total, all-cause mortality	Durvalubmab + Tremelimumab	2	40
Total, other adverse events	Durvalubmab	39	40
Total, other adverse events	Durvalubmab + Tremelimumab	38	40
Total, serious adverse events	Durvalubmab	13	40
Total, serious adverse events	Durvalubmab + Tremelimumab	7	40

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
34103352	DERIVED	PubMed
36493574	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons3

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Durvalubmab vs Durvalubmab + Tremelimumab: Treatment Efficacy Determined by Measuring the Overall Response Rate	Trial comparisons
Durvalubmab vs Durvalubmab + Tremelimumab: deaths from any cause	Trial comparisons
Durvalubmab vs Durvalubmab + Tremelimumab: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03015129

GET https://conductscience.org/api/trials/v1/NCT03015129/events?page=2

API reference For AI assistants